ConCallIQ
Go Pro
AARTIDRUGS Diversified 30 Apr 2026

Aarti Drugs Limited — Q4 FY26

Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin).

neutral medium
Compare with...
Revenue ₹721 Cr +6%
EBITDA ₹97 Cr
PAT ₹55 Cr -12%
EBITDA Margin 13.4%
Duration 52 min
Read Time 1 min read

Financial stats pending filing verification

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Sustained high crude prices hurting antibiotic demand

If crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.

high · management_commentary
R

Salicylic acid plant turnaround delayed

Salicylic acid production remains shut due to equipment delays and variable losses; restart depends on successful installation and testing.

medium · management_commentary
R

Methylamine ramp-up dependent on metformin expansion

Higher utilization of the methylamine plant requires commensurate metformin production expansion, which is still underway.

medium · analyst_question
R

Geopolitical disruptions impacting raw material supply

West Asia war caused ammonia shortages in March; further escalation could disrupt key raw material availability.

high · data_observation